CZ 112

Drug Profile

CZ 112

Alternative Names: 9-Nitrocamptothecin propionate; Rubitecan prodrug

Latest Information Update: 20 Apr 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator The Stehlin Foundation for Cancer Research
  • Developer SuperGen
  • Class Antineoplastics; Camptothecins; Small molecules
  • Mechanism of Action DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 13 Jul 2004 This compound is still in active development
  • 17 Feb 2000 A preclinical study has been added to the pharmacodynamics section
  • 05 Jan 1999 Phase-I clinical trials in Cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top